Frouws et al. (Frouws et al. 2017) described a benefit for overall patient survival with wild-type-BRAF tumours (RR = 0.60 (95% CI: 0.44–0.83) and no association between KRAS mutation status and aspirin use after diagnosis of CRC. This evidence concerns the gene KRAS and colorectal carcinoma.